Skip to main content

Table 1 Prognostic signatures for STAD

From: Features of alternative splicing in stomach adenocarcinoma and their clinical implication: a research based on massive sequencing data

Type

Formula

Hazard ratio

(95%CI)

AUC

AA

ST5–14270-AA*(− 5.351641) + PLK4–70545-AA*(− 50.075071) + BDKRB2–29192-AA*(− 2.251191) + NAT6–64990-AA*2.558247 + APOBEC3B-62,269-AA*(− 58.382634) + ECT2–67658-AA*(− 9.149068) + MORF4L2–89,778-AA*(− 2.400196) + STAT3–41041-AA*3.052117 + PARPBP-24045-AA*(− 3.451740) + CBX7–62286-AA*5.771950 + TRAPPC2L-38,043-AA*5.892537 + C19orf60–48,492-AA*(− 2.837545) + DHPS-47831-AA*(− 3.486833) + TROAP-21565-AA*2.928574 + ZNF410–28332-AA*13.901426 + HNRNPR-1047-AA*2.702840

1.034 (1.021–1.047)

0.843

AD

UBA52–48486-AD*(− 3.817624) + PHRF1–13700-AD*(− 2.535869) + TCIRG1–17286-AD*(− 15.912327) + CCDC51–64653-AD*(− 1.376775) + HMBS-19096-AD*(− 1.858043) + SNX27–7647-AD*(− 10.039140) + RAP1B-22,959-AD*(− 5.215765) + SERPINA3–29154-AD*(− 4.624829) + RPS6KA4–16,651-AD*14.672505 + MBD4–66720-AD*(− 3.903928) + NKG7–51322-AD*(− 13.306358) + RALGPS1–87614-AD*(− 4.395804) + TMEM106C-21,404-AD*(− 5.264665) + FAH-32181-AD*(− 0.998076) + SMIM19–83739-AD*(− 1.958156) + HYI-2185-AD*5.019022

1.175 (1.136–1.215)

0.841

AP

KIAA1147–82046-AP*(− 26.932098) + CDKN3–27569-AP*(− 16.593603) + WEE1–14328-AP*(− 4.589803) + RCAN1–60494-AP*0.979582 + MID1–88465-AP*3.529023 + TUBA1A-21,538-AP*7.031309 + PDZK1IP1–2893-AP*(− 77.071138)

1.072 (1.047–1.099)

0.71

AT

PPHLN1–21214-AT*4.712066 + ABCB5–78909-AT*1.406777 + TLN2–30978-AT*(− 3.649182) + TET2–70188-AT*2.736038 + MFSD2B-52,798-AT*(− 4.976167) + BRSK1–52060-AT*(− 3.402968) + ZC3H12D-78,076-AT*1.091190 + IL7R-71,774-AT*(− 4.704211) + ZNF846–47399-AT*1.093000 + ZFYVE28–68559-AT*(− 1.498791)

1.183 (1.130–1.239)

0.77

ES

CD44–14986-ES*(− 5.431100) + RASSF4–11351-ES*(− 15.542342) + PPP2R5D-76,200-ES*(− 9.142504) + LOH12CR1–20,507-ES*(− 14.620773) + CBWD3–86515-ES*2.727266 + GNPDA2–69151-ES*(− 13.336665) + EIF3K-49,681-ES*(− 5.515884) + CLEC4A-20,178-ES*(− 4.701354) + FANCA-38149-ES*(− 378.778875) + ZNF106–30164-ES*(− 34.393642) + NME6–64602-ES*(− 23.597673) + PAOX-13555-ES*(− 2.845972) + DYNC2H1–18,489-ES*(− 7.577542) + CYP2B6–50,020-ES*(− 1.561095) + TMX2–15906-ES*(− 4.527987) + D2HGDH-58,425-ES*(− 16.861342) + DUSP22–75134-ES*(− 16.679166)

1.037 (1.028–1.046)

0.816

ME

ANK3–11852-ME*0.617693 + AMT-64866-ME*9.363879 + C4orf21–70,379-ME*8.722888 + MCFD2–102349-ME*(− 2.786243) + CS-22420-ME*1.961533 + MTHFSD-102413-ME*3.738460 + KDM6A-98,323-ME*(− 1.285022) + ATE1–91855-ME*(− 2.737012) + USP10–37863-ME*1.511545 + RAB6A-17,707-ME*2.671001 + GRB10–79717-ME*1.261053 + ITGB1–126615-ME*1.273771

1.636 (1.436–1.863)

0.781

RI

SRSF7–53276-RI*(− 1.721712) + RPS15–46490-RI*(− 2.387697) + DTD2–27118-RI*(− 6.362278) + DUSP18–61796-RI*(− 5.322993) + ADRA2C-68,651-RI*(− 5.026148) + LGALS3BP-43,940-RI*(− 2.549496) + BICD2–86883-RI*(− 1.137099) + ALS2CL-64,462-RI*1.664472 + THAP7–61211-RI*(− 1.872850) + KAT5–16914-RI*(− 1.868716)

1.138 (1.097–1.180)

0.902

All

CD44–14986-ES*(− 6.883160) + PPHLN1–21214-AT*5.396354 + RASSF4–11351-ES*(− 14.293402) + KIAA1147–82046-AP*(− 22.278949) + PPP2R5D-76,200-ES*(− 6.035515) + LOH12CR1–20,507-ES*(− 10.075293) + CDKN3–27569-AP*(− 18.653016) + UBA52–48486-AD*(− 3.222755) + CADPS-65499-AT*(− 1.957771) + SRSF7–53276-RI*(− 2.217781) + WEE1–14328-AP*(− 5.279043)

1.043 (1.030–1.057)

0.882